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1134Background:We performed the present systematic review and meta-analysis of randomized and nonrandomized
comparative studies in an attempt to compare the safety and efficacy of drug-eluting stents with coronary artery
bypass grafting for patients with coronary artery disease.
Methods: Twenty-five eligible comparative studies (1 randomized and 24 nonrandomized) were assessed. Two
reviewers independently appraised each study. Meta-analysis was performed by combining the results of reported
incidence of morbidity, mortality, and repeat revascularization. The relative risk was used as a summary statistic.
Results: In these 25 studies 34,278 patients were compared, of whom 18,538 received drug-eluting stents and
15,740 underwent coronary artery bypass grafting. It must be acknowledged that this comparison represented a se-
lected group of patients who received drug-eluting stents or underwent coronary artery bypass grafting. The ac-
cumulative incidences of all-cause mortality at 12 months (4.5% vs 4.0%, P ¼ .92) and 24 months (6.2% vs
8.4%, P ¼ .27) and 30-day myocardial infarction (1.4% vs 2.0%, P ¼ .60) were similar, respectively, between
the drug-eluting stent and coronary artery bypass grafting groups. Drug-eluting stents were associated with lower
rates of all-cause mortality at 30 days (0.9% vs 2.3%, P< .001), stroke (0.4% vs 1.7%, P< .001), and 30-day
major adverse cardiac and cerebrovascular events (3.6% vs 5.5%, P<.04). However, the coronary artery bypass
grafting group had a lower incidence of postprocedural myocardial infarction (5.5% vs 4.7%, P ¼ .03), repeat
revascularization (22.2% vs 4.1%, P< .001), and 12-month major adverse cardiac and cerebrovascular events
(16.7% vs 10.5%, P< .001). Subgroup analysis of patients with multivessel coronary artery disease showed
similar results.
Conclusions: Drug-eluting stents are associated with less periprocedural risks but a higher incidence of postpro-
cedural myocardial infarction, repeat revascularization, and 12-month major adverse cardiac and cerebrovascular
events compared with coronary artery bypass grafting. (J Thorac Cardiovasc Surg 2011;141:1134-44)Earn CME credits at
http://cme.ctsnetjournals.org
Coronary artery bypass grafting (CABG) and percutaneous
coronary intervention (PCI) are alternative revascularization
techniques for symptomatic patients with coronary artery
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The Journal of Thoracic and Cardiovascular Surtechnological advent have expanded its use in patients with
severe coronary artery disease and complex anatomic le-
sions. A meta-analysis byMercado and colleagues2 compar-
ing randomized controlled trials (RCTs) of PCI with bare
metal stents (BMSs) versus CABG demonstrated similar
degrees of protection against death, myocardial infarction,
and stroke for patients with multivessel coronary artery
disease at 1 year after the initial procedure. However, repeat
revascularization procedures remained more likely after use
of BMSs. A subsequent meta-analysis by Daemen and co-
workers3 comparing RCTs on the long-term outcomes be-
tween PCI with BMSs and CABG (the Stent of Surgery
trial, the Arterial Revascularization Therapies Study, Edstu-
dio Randomizado Argentino de Angioplastia vs Cirugia II,
and theMedicine, Angioplasty or Surgery Study II) indicated
that BMSs were associated with a long-term safety profile
similar to that of CABG but also reinforced higher revascu-
larization and major adverse cardiac and cerebrovascular
events (MACCEs) in the BMS group.3
Drug-eluting stents (DES) demonstrate similar rates of
death and myocardial infarction but reduced rates of repeatgery c May 2011
Abbreviations and Acronyms
BMS ¼ bare metal stent
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
DES ¼ drug-eluting stent
MACCE ¼ major adverse cardiac and
cerebrovascular event
PCI ¼ percutaneous coronary intervention
RCT ¼ randomized controlled trial
RR ¼ relative risk
SYNTAX ¼ Synergy Between PCI with Taxus
and Cardiac Surgery
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Drevascularization compared with BMSs,4 thus increasing the
percentage of patients with multivessel disease treated with
PCI. However, recent data suggested a higher rate of throm-
botic occlusion with DESs than BMSs.5 The recent Synergy
Between PCI with Taxus and Cardiac Surgery (SYNTAX)
trial compared DESs versus CABG in patients with triple-TABLE 1. Summary of 25 comparative studies included in the present sys
Reference Study design Study population St
Ben-Gal and coworkers9 OC DM 2
Ben-Gal and coworkers10 OC LAD 2
Briguori and coworkers11 OC MVD, LAD, DM, OPCAB 2
Cheng and coworkers12 OC LMCAD 2
Chieffo and coworkers13 OC LMCAD 2
Domı´nguez-Franco and
coworkers14
OC MVD, LAD, DM 2
Gioia and coworkers15 OC LV dysfunction 2
Hannan and coworkers16 OC MVD 2
Hong and coworkers17 OC LAD
Javaid and coworkers18 OC MVD
Kukreja and coworkers19 OC MVD, LAD 1
White and coworkers20 OC LMCAD 2
Li and coworkers21 OC MVD 2
Ma¨kikallio and coworkers22 OC LMCAD 2
Moshkovitz and coworkers23 OC LAD, OPCAB 2
Palmerini and coworkers24 OC LMCAD 2
Park and coworkers25 OC MVD 2
Sanmartı´n and coworkers26 OC LMCAD 2
Serruys and coworkers6 RCT MVD or LMCAD 2
Tarantini and coworkers27 OC MVD, DM 2
Toutouzas and coworkers28 OC LAD, DM 2
van Domburg and
coworkers29
OC MVD or LMCAD
Yang30 OC MVD 2
Yang and coworkers31 OC MVD 2
Yi and coworkers32 OC MVD, OPCAB 2
SD, Standard deviation; DES, drug-eluting stent; CABG, coronary artery bypass grafting; O
descending coronary artery;MVD, multivessel disease; OPCAB, off-pump coronary artery b
controlled trial. *Median.
The Journal of Thoracic and Carvessel or left main coronary artery disease.6 This RCT dem-
onstrated that at 12 months the rates of death and myocardial
infarction were similar between the 2 groups, but DESs were
associated with a significantly higher rate of MACCEs
(17.8% vs 12.4%, P ¼ .002) and lower rate of stroke
(0.6% vs 2.2%, P ¼ .003). As is generally true with
RCTs, the study population is predefined and hence subject
to trial design bias. We performed the present systematic re-
view and meta-analysis of the randomized and nonrandom-
ized comparative studies in an attempt to assess the safety
and efficacy of DESs versus CABG with the current clinical
evidence.
METHODS
Search Strategy
Electronic searches were performed in 6 databases from their inception
to September 2009: Medline, Embase, Pubmed, Cochrane Central Register
of Controlled Trials, Cochrane Database of Systematic Reviews, and Data-
base of Abstracts of Review of Effectiveness. To achieve the maximum
sensitivity of the search strategy and identify all trials comparing DESs
and CABG, we used appropriate free text and thesaurus terms, including
‘‘percutaneous coronary intervention,’’ ‘‘coronary angioplasty,’’ ‘‘coro-
nary artery stenting,’’ ‘‘drug-eluting stent,’’ and ‘‘coronary artery bypasstematic review
No. of patients
Age of cohort
(mean ± SD)
Ejection fraction
(mean ± SD)
udy period DES CABG DES CABG DES CABG
002–2005 86 86 NA NA NA NA
002–2003 83 83 NA NA NA NA
002–2004 69 149 63  9 66  9 54  12 53  9
000–2007 94 216 68  10 67  9 56  17 56  20
002–2004 107 142 64  10 68  10 52  10 52  11
000–2004 128 142 68 65 52  13 54  14
002–2005 128 92 69  10 68  10 28  6 27  8
003–2005 9963 7437 65  12 66  11 NA NA
2003 119 70 61  10 61  10 53  9 52  9
NA 979 701 66  11 65  11 NA NA
997–2003 289 206 63  10 62  9 59  12 61  13
003–2005 50 123 72  15 70  10 51  15 52  10
004–2005 1834 1886 58  10 61  9 NA NA
005–2007 49 238 72  10 70  9 55  12 54  11
002–2003 116 116 NA NA NA NA
003–2006 98 161 81* 78* 50* 53*
003–2005 1547 1495 62  10 62  9 59  9 56  11
000–2005 96 245 66  13 66  10 NA NA
005–2007 903 897 65  10 65  10 NA NA
004–2005 93 127 65  9 67  7 62  14 62  14
001–2006 39 38 59  13 61  10 48  7 49  9
2002 798 275 62  11 64  11 NA NA
003–2004 235 231 65  10 65  10 51  9 50  11
003–2005 441 390 63  10 63  8 58  12 53  14
003–2005 194 194 63  10 62  9 NA NA
C, observational cohort; DM, diabetes mellitus; NA, not applicable; LAD, left anterior
ypass; LMCAD, left main coronary artery disease; LV, left ventricle; RCT, randomized
diovascular Surgery c Volume 141, Number 5 1135
TABLE 2. Follow-up data of 25 comparative studies included in the present systematic review
Reference
Total patients enrolled
(DES/CABG)
Total patients included
in study (DES/CABG)
Follow-up
periods (mo)
No. of patients at
last follow-up (%)
Ben-Gal and coworkers9 518 (176/342) 172 (86/86) 18 Not mentioned
Ben-Gal and coworkers10 376 (272/104) 166 (83/83) 22 Not mentioned
Briguori and coworkers11 355 218 (69/149) 12 218 (100%)
Cheng and coworkers12 Not mentioned 363 (94/216) 27 325 (90%)
Chieffo and coworkers13 Not mentioned 249 (107/142) 12 249 (100%)
Domı´nguez-Franco and coworkers14 Not mentioned 270 (128/142) 24 263 (97.4%)
Gioia and coworkers15 230 220 (128/92) 15 220 (100%)
Hannan and coworkers16 29,095 17,400 (9963/7437) 18 Not mentioned
Hong and coworkers17 Not mentioned 189 (119/70) 6 184 (97%)
Javaid and coworkers18 Not mentioned 1680 (979/701) 12 Not mentioned
Kukreja and coworkers19 1812 682 (289/206) 36 682 (100%)
White and coworkers20 Not mentioned 173 (50/123) 6 Not mentioned
Li and coworkers21 Not mentioned 3720 (1834/1886) 36 3679 (98.9%)
Ma¨kikallio and coworkers22 6705y 287 (49/238) 12 Not mentioned
Moshkovitz and coworkers23 522 (168/354) 232 (116/116) 12 Not mentioned
Palmerini and coworkers24 259 259 (98/161) 24 258 (99.6%)
Park and coworkers25 Not mentioned 3042 (1547/1495) 36 Not mentioned
Sanmartı´n and coworkers26 Not mentioned 341 (96/245) 12 334 (98%)
Serruys and coworkers6 4337 1800 (903/897) 12 1740 (96.7%)
Tarantini and coworkers27 Not mentioned 220 (93/127) 24 220 (100%)
Toutouzas and coworkers28 314 (191/123) 77 (39/38) 20 77 (100%)
van Domburg and coworkers29 1073* 1073 (798/275) 15 1073 (100%)
Yang and coworkers30 Not mentioned 466 (235/231) 25 436 (93.6%)
Yang and coworkers31 1212 831 (441/390) 12 795 (95.7%)
Yi and coworkers32 508 (267/241) 388 (194/194) 36 382 (98.5%)
DES, Drug-eluting stent; CABG, coronary artery bypass grafting. *Control group not included. yAll patient undergoing coronary angiographic analysis.
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Dgrafting.’’ The reference lists of all retrieved articles were reviewed for
further identification of potentially relevant studies.
Study Selection
All studies assessing DESs versus CABG for coronary artery disease
published in English were included. We excluded studies that did not in-
clude a comparative group that contained CABG as a form of intervention.
When centers have published duplicate trials with accumulating numbers of
patients or increased lengths of follow-up, only the most recent or complete
reports were included for qualitative appraisal and meta-analysis. The pub-
lication types of letters, editorials, or reviews were excluded.
Data Extraction and Critical Appraisal
Two investigators (R.P. and T.D.Y.) independently reviewed each in-
cluded article. Discrepancies between the 2 investigators were resolved
by means of discussion and consensus with a senior investigator. The final
results were reviewed by 3 senior investigators (M.K.W., P.G.B., and
M.P.V.). Time points for analysis of outcomes were 30 days, 1 year, 2 years,
and greater than 2 years. Data regarding the end points were extracted and
reported separately as all-cause mortality at 30 days, all-cause mortality at
12 months, all-cause mortality at 24 months, all-cause stroke at last
follow-up, 30-day myocardial infarction, myocardial infarction at last
follow-up, repeat revascularization, 30-dayMACCEs, and 12-monthMAC-
CEs. Where data were available, the following subgroups for analysis were
proposed: vessels involved (left anterior descending coronary artery dis-
ease, left main coronary artery disease, and multivessel coronary artery dis-
ease), surgical intervention (standard CABG and off-pump coronary artery
bypass), and comorbidities (diabetes). Because of the lack of a large number
of patients to generate robust clinical conclusions, only multivessel disease
was subject to separate analysis.1136 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
Meta-analysis was performed by combining the results of reported
incidence of morbidity, all-cause mortality, and repeat revascularization.
The relative risk (RR) was used as a summary statistic. In this study both
fixed- and random-effects models were tested. In a fixed-effects model it
was assumed that treatment effect in each study was the same, whereas in
a random-effects model it was assumed that there were variations between
studies, and the calculated ratios thus had more conservative value.7 c2
Tests were used to study heterogeneity between trials. The I2 statistic was
used to estimate the percentage of total variation across studies because
of heterogeneity rather than chance. The I2 statistic can be calculated as fol-
lows: I2¼ 100%3 (Qdf)/Q, withQ defined as Cochrane’s heterogeneity
statistics and df defined as degree of freedom.8 An I2 value of greater than
50% was considered substantial heterogeneity. If there was substantial het-
erogeneity, the possible clinical and methodological reasons for this were
explored qualitatively. In the present meta-analysis the results using the
random-effects model were presented to take into account the possible clin-
ical diversity andmethodological variation among studies. Specific analyses
considering confounding factors were not possible because raw data were
not available. All P values were 2-sided. All statistical analysis was
conducted with Review Manager Version 4.2 (Cochrane Collaboration,
Software Update, Oxford, United Kingdom).RESULTS
Quantity and Quality of Trials
A total of 616 references were identified through elec-
tronic database searches. After exclusion of duplicate or ir-
relevant references, 557 potentially relevant articles were
retrieved for more detailed evaluation. An additional 3gery c May 2011
FIGURE 1. Forest plot of the relative risk (RR) of all-cause mortality after drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for
coronary artery disease. The estimate of the RR of each trial corresponds to the middle of the squares, and the horizontal line shows the 95% confidence
interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For each subgroup,
the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within
a subgroup is given below the summary statistics.
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Dpotentially relevant reports were identified through scanning
of reference lists. When inclusion and exclusion criteria
were applied, 36 comparative studies remained for assess-
ment. Four duplicate publications in which investigators
reported initial accumulating numbers of participants or in-
creased length of follow-up were excluded. Three studies
were excluded because primary outcome data were notThe Journal of Thoracic and Caravailable. Four studies were withdrawn from the analysis be-
cause the treatment outcomes contained a mixture of DESs
and BMSs. The final 25 most definitive reports (1 RCT6
and 24 nonrandomized comparative studies9-32) were
included for appraisal and data extraction (Table 1).6,9-32
In these 25 studies 34,278 patients were compared, of
whom 18,538 underwent PCI with DESs and 15,740diovascular Surgery c Volume 141, Number 5 1137
FIGURE2. Forest plot of the relative risk (RR) of all-cause stroke after drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for coronary
artery disease. The studies were analyzed according to the type of morbidity andmortality. The estimate of the RR of each trial corresponds to themiddle of the
squares, and the horizontal line shows the 95% confidence interval (CI). On each line, the numbers of events as a fraction of the total number randomized are
shown for both treatment groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds.
A test of heterogeneity between the trials within a subgroup is given below the summary statistics.
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Dunderwent CABG.6,9-32 Seven studies focused on 1640
patients with left anterior descending coronary artery
disease.10,11,14,17,19,23,28 Six studies compared DESs versus
CABG in 1619 patients with left main coronary artery
disease.12,13,20,22,24,26 Eleven studies assessed 28,693
patients with multivessel disease.11,14,16,18,19,21,25,27,30-32
Five studies focused on 950 diabetic patients with
coronary artery disease.9,11,14,27,28 Three studies compared
DESs versus off-pump coronary artery bypass surgery in
838 patients.11,23,32
This comparison represented a selected group of patients,
in that not all patients who were initially screened underwent
treatments (Table 2).6,9-32 Follow-up periods varied among
studies and were mostly focused on short-term or midterm
outcomes. Twenty-three studies6,9-16,18,19,21-32 had at least 1
year of follow-up, 9 studies12,14,19,21,24,25,27,30,32 had at least
2 years of follow-up, and 4 studies19,21,25,32 provided 3-year
follow-up data. Seventeen studies6,11-15,17,19,21,24,26-32
reported the numbers of patients available at the last follow-
up, and this ranged from 90% to 100%.1138 The Journal of Thoracic and Cardiovascular SurAssessment of Morbidity and Mortality
All-cause mortality was lower with DESs at 30 days
(0.9% vs 2.3%; RR, 0.50; 95% confidence interval [CI],
0.34–0.75; P< .001; I2 ¼ 0%) and similar between DESs
and CABG at 12 months (4.5% vs 4.0%; RR, 0.98; 95%
CI, 0.61–1.56; P ¼ .92; I2 ¼ 61.6%) and 24 months
(6.2% vs 8.4%; RR, 0.81; 95% CI, 0.55–1.18; P ¼ .27;
I2 ¼ 0%; Figure 1). Seventeen studies6,11-14,17-22,25-27,30-32
compared the incidence of stroke and demonstrated
that DESs were associated with a lower incidence of
stroke at last follow-up (0.4% vs 1.7%; RR, 0.33; 95%
CI, 0.22–0.50; P<.001; Figure 2). There was no substantial
heterogeneity among the randomized and nonrandomized
studies (I2¼ 0%; heterogeneity P¼ .77). Composite results
from 2 studies11,32 on DESs versus off-pump coronary artery
bypass surgery showed that there was no significant differ-
ence in the accumulative stroke rate in 606 patients
(0.4% vs 1.7%, respectively; RR, 0.64; 95% CI, 0.04–
11.45; P ¼ .76; I2 ¼ 44.7%). Seventeen stud-
ies9,11-14,17,20,21,23,24,26-32 showed similar accumulativegery c May 2011
FIGURE 3. Forest plot of the relative risk (RR) of myocardial infarction after drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for
coronary artery disease. The estimate of the RR of each trial corresponds to the middle of the squares, and the horizontal line shows the 95% confidence
interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For each subgroup,
the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within
a subgroup is given below the summary statistics.
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Dincidence of 30-day myocardial infarction between DESs
and CABG (1.4% vs 2.0%; RR, 0.88; 95% CI, 0.54–1.43;
P ¼ .60), and there was no substantial heterogeneity among
the studies (I2 ¼ 32%; heterogeneity P ¼ .11; Figure 3).
Twenty-three studies6,9-11,13-19,21-32 compared the overall
incidence of myocardial infarction at last follow-up and dem-
onstrated that CABGwas associatedwith a lower rate of post-
procedural myocardial infarction (5.5% vs 4.7%; RR, 1.11;The Journal of Thoracic and Car95% CI, 1.01–1.22; P¼ .03), and there was no heterogeneity
among the randomized and nonrandomized studies (I2¼ 0%;
heterogeneity P ¼ .48; Figure 3).
Twenty-three studies6,9-17,19,21-32 reported the incidence
of repeat revascularization and demonstrated that DESs
were associated with a higher rate of repeat
revascularization (22.2% vs 4.1%; RR, 3.75; 95% CI,
2.80–5.02; P< .001; I2 ¼ 77.0%; Figure 4). Subgroupdiovascular Surgery c Volume 141, Number 5 1139
FIGURE 4. Forest plot of the relative risk (RR) of repeat revascularization after drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for
coronary artery disease. The estimate of the RR of each trial corresponds to the middle of the squares, and the horizontal line shows the 95% confidence
interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For each subgroup,
the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within
a subgroup is given below the summary statistics.
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Danalyses of 8 studies11-13,17,23,26,31,32 with 1 year of
follow-up (8.8% vs 2.0%; RR, 3.81; 95% CI, 2.35–
6.18; P < .001; I2 ¼ 17.3%), 7 studies9,10,15,16,22,28,29
with 2 years of follow-up (28.2% vs 5.0%; RR, 4.27;
95% CI, 2.81–6.49; P < .001; I2 ¼ 37.5%), 7 stud-
ies14,19,21,24,25,27,30 with more than 2 years of follow-up
(12% vs 2.9%; RR, 3.95; 95% CI, 2.20–7.10; P< .001;
I2 ¼ 83.4%), and the RCT6 (13.5% vs 5.6%; RR, 2.29;
95% CI, 1.67–3.14; P< .001) all demonstrated that the1140 The Journal of Thoracic and Cardiovascular Surrates of repeat revascularization were significantly higher
with DESs compared with those seen after CABG
(Figure 4).
Combined results showed that the accumulative incidence
of MACCEs at 30 days was significantly lower with DESs
(3.6% vs 5.5%; RR, 0.56; 95% CI, 0.32–0.98; P ¼ .04;
I2 ¼ 51.3%) but much higher with DESs at 12 months
(16.7% vs 10.5%; RR, 1.61; 95% CI, 1.23–2.12;
P< .001; I2 ¼ 68.2%; Figure 5).gery c May 2011
FIGURE 5. Forest plot of the relative risk (RR) of major cardiac and cerebrovascular events (MACCE) after drug-eluting stents (DES) versus coronary artery
bypass grafting (CABG) for coronary artery disease. The estimate of the RR of each trial corresponds to themiddle of the squares, and the horizontal line shows
the 95% confidence interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For
each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity between the
trials within a subgroup is given below the summary statistics.
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In studies11,14,16,18,19,21,25,27,30-32 assessing patients with
multivessel coronary artery disease, the accumulative rates
of 30-day myocardial infarction (0.8% vs 1.1%; RR,
0.99; 95% CI, 0.51–1.51; P ¼ .64; I2 ¼ 0%) and
myocardial infarction at last follow-up (5.9% vs 5.1%;
RR, 1.17; 95% CI, 0.92–1.49; P ¼ .19; I2 ¼ 21.1%) were
similar between the DES group and the CABG group
(Figure 6). The accumulative incidence of repeat revascular-
ization was higher in the DES group compared with that seen
in the CABG group (24.4% vs 4.2%; RR, 4.03; 95% CI,
2.70–6.01; P< .001; I2 ¼ 84.4%). The accumulative inci-
dence of MACCEs was lower in the DES group compared
with that in the CABG group at 30 days (2.0% vs 4.1%;
RR, 0.58; 95% CI, 0.35–0.97; P ¼ .04; I2 ¼ 0%) but was
higher in the DES group at 12 months (16.1% vs 8.6%;
RR, 1.74; 95% CI, 1.24–2.44; P ¼ .001; I2 ¼ 55.1%).DISCUSSION
Since 2002, DESs have been shown to reduce repeat re-
vascularization rates without affecting the short- and long-The Journal of Thoracic and Carterm safety of the treatment.4,33 The recently published
SYNTAX trial demonstrated that in patients with triple-
vessel or left main coronary artery disease at 12 months,
the rates of death and myocardial infarction were similar
between the DES and CABG groups, and DESs were asso-
ciated with a lower rate of stroke (0.6% vs 2.2%,
P ¼ .003).6 However, for the primary end point, 12-month
MACCEs, the noninferiority of use of DESs compared
with CABG was not demonstrated; CABG was proved to
be superior (17.8% vs 12.4%, P ¼ .002).6 Other large-
scale RCTs, such as Future Revascularization Evaluation
in Patients with Diabetes: Optimal Management of Multi-
vessel Disease and Coronary Artery Revascularization in
Diabetics, are ongoing.
The presentmeta-analysis demonstrated the following key
findings: the accumulative incidences of all-cause mortality
at 12 and 24 months and 30-day myocardial infarction
were similar between the 2 groups. DESs were associated
with lower rates of all-cause mortality at 30 days, stroke,
and 30-day MACCEs; however, the CABG group had
a lower incidence of overall myocardial infarction at
last follow-up, repeat revascularization, and 12-monthdiovascular Surgery c Volume 141, Number 5 1141
FIGURE 6. Forest plot of the relative risk (RR) of 30-day myocardial infarction, myocardial infarction at last follow-up, repeat revascularization, and 30-day
and 12-month major cardiac and cerebrovascular events (MACCE) after drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for multi-
vessel coronary artery disease. The estimate of the RR of each trial corresponds to the middle of the squares, and the horizontal line shows the 95% confidence
interval (CI). On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment groups. For each subgroup, the
sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within a sub-
group is given below the summary statistics.
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DMACCEs. Subgroup analysis on patients with multivessel
coronary artery disease showed similar results. The present
meta-analysis emphasized that in assessing use of DESs ver-
sus CABG, one must consider the relative merits of the
CABG procedure with lasting benefits against less-invasive
DESs with traditionally higher rates of reintervention.
Although procedural success rates are high and periproce-
dural complication rates are relatively low with PCI, rates of
restenosis, which might require reintervention, have tradi-
tionally been a significant limitation of coronary stenting.
The advent of antiproliferative DESs has dramatically
reduced target-lesion and target-vessel restenosis and the
incidence of repeat revascularization compared with
BMSs.4,33,34 However, there is still a lack of high-level clin-
ical evidence on the use of DESs for patients with multives-
sel disease. Because of the aging population in Western
countries and a growing incidence of coronary artery disease
in the developing world, multivessel revascularization is in-
creasing. Most of these patients have significant comorbid-
ities. Hannan and colleagues16 identified 17,400 patients
with multivessel disease from a large-scale registry and dem-
onstrated that CABG was associated with lower 18-month
rates of repeat revascularization, death, and/or myocardial
infarction compared with DESs. The present meta-analysis
on both randomized and nonrandomized comparative stud-
ies confirmed that CABG was still more effective than
DESs in reducing 12-month MACCEs and the need for
target-vessel revascularization and confirmed the advan-
tages of CABG as the standard of care for patients with
multi-vessel coronary artery disease in real-world clinical
practice.
It needs to be acknowledged that (1) the data included in
the present meta-analysis were mostly extrapolated from
nonrandomized studies, which are subject to selection
bias; (2) this comparison represented a subset of patients
who were initially enrolled or screened for treatments; and
(3) although not clearly stated in each study, from the SYN-
TAX registry, we know that at least one third of patients un-
dergoing CABG are ineligible for PCI because of
complexity of lesions, and in the absence of comparison of
the baseline characteristics among all the studies, it is rea-
sonable to assume that there were confounding factors in al-
locating patients to undergo either CABG or PCI and
patients who underwent CABG had more complex disease.
In the current meta-analysis the accumulative results from
the observational cohorts demonstrated concordant results
to the SYNTAX trial,6 and this might reflect the outcomes
in a more heterogeneous group of patients in clinical prac-
tice. As with any meta-analysis, the conclusions drawn
from such data are subject to the limitations of the original
included studies and the differences in patients and tech-
niques among different centers. The validity of the effect es-
timates in the studies depends on factors such as the
recruitment of inception cohorts, patient selection criteria,The Journal of Thoracic and Carand length of follow-up. Clinical follow-up to date is still
limited at the short-term to midterm threshold, which might
capture most of the repeat procedures needed with stent tech-
nology, but does not have sufficient follow-up to capture
even half of the graft failures, which would require 10 years.
It is understood that the survival benefit of CABG could not
be fully demonstrated when most studies only had limited
follow-up. Large-scale RCTs with long follow-up will pro-
vide complementary data comparing DESs and CABG, es-
pecially in the context of late stent thrombosis, but the rate
of technological advancement is likely to make the results
of such trials obsolete.
Although DESs are associated with less periprocedural
risks, the current literature suggests that DESs are inferior
to CABG in terms of a higher incidence of postprocedural
myocardial infarction, repeat revascularization, and 12-
month MACCEs.
We thank Professor Deborah Black for statistical analysis.References
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